|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2019. CA Cancer J Clin. 69:7–34. 2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Liu CY, Chen KF and Chen PJ: Treatment of
liver cancer. Cold Spring Harb Perspect Med.
5(a021535)2015.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Li L and Wang H: Heterogeneity of liver
cancer and personalized therapy. Cancer Lett. 379:191–197.
2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Marin JJG, Cives-Losada C, Asensio M,
Lozano E, Briz O and Macias RIR: Mechanisms of anticancer drug
resistance in hepatoblastoma. Cancer (Basel).
11(407)2019.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Keating GM: Sorafenib: A review in
hepatocellular carcinoma. Target Oncol. 12:243–253. 2017.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Zhu YJ, Zheng B, Wang HY and Chen L: New
knowledge of the mechanisms of sorafenib resistance in liver
cancer. Acta Pharmacol Sin. 38:614–622. 2017.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Liu MM, Bandaru V, Bond JP, Jaruga P, Zhao
X, Christov PP, Burrows CJ, Rizzo CJ, Dizdaroglu M and Wallace SS:
The mouse ortholog of NEIL3 is a functional DNA glycosylase in
vitro and in vivo. Proc Natl Acad Sci USA. 107:4925–4930.
2010.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Bandaru V, Sunkara S, Wallace SS and Bond
JP: A novel human DNA glycosylase that removes oxidative DNA damage
and is homologous to Escherichia coli endonuclease VIII. DNA Repair
(Amst). 1:517–529. 2002.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Liu M, Doublie S and Wallace SS: Neil3,
the final frontier for the DNA glycosylases that recognize
oxidative damage. Mutat Res. 743-7444–11. 2013.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Jalland CM, Scheffler K, Benestad SL,
Moldal T, Ersdal C, Gunnes G, Suganthan R, Bjørås M and Tranulis
MA: Neil3 induced neurogenesis protects against prion disease
during the clinical phase. Sci Rep. 6(37844)2016.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Sejersted Y, Hildrestrand GA, Kunke D,
Rolseth V, Krokeide SZ, Neurauter CG, Suganthan R, Atneosen-Åsegg
M, Fleming AM, Saugstad OD, et al: Endonuclease VIII-like 3 (Neil3)
DNA glycosylase promotes neurogenesis induced by hypoxia-ischemia.
Proc Natl Acad Sci USA. 108:18802–18807. 2011.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Regnell CE, Hildrestrand GA, Sejersted Y,
Medin T, Moldestad O, Rolseth V, Krokeide SZ, Suganthan R, Luna L,
Bjørås M and Bergersen LH: Hippocampal adult neurogenesis is
maintained by Neil3-dependent repair of oxidative DNA lesions in
neural progenitor cells. Cell Rep. 2:503–510. 2012.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Skarpengland T, Holm S, Scheffler K,
Gregersen I, Dahl TB, Suganthan R, Segers FM, Østlie I, Otten JJ,
Luna L, et al: Neil3-dependent base excision repair regulates lipid
metabolism and prevents atherosclerosis in Apoe-deficient mice. Sci
Rep. 6(28337)2016.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Yang LX, Zhang X and Zhao G: Ginsenoside
Rd attenuates DNA damage by increasing expression of DNA
glycosylase endonuclease VIII-like proteins after focal cerebral
ischemia. Chin Med J (Engl). 129:1955–1962. 2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Massaad MJ, Zhou J, Tsuchimoto D, Chou J,
Jabara H, Janssen E, Glauzy S, Olson BG, Morbach H, Ohsumi TK, et
al: Deficiency of base excision repair enzyme NEIL3 drives
increased predisposition to autoimmunity. J Clin Invest.
126:4219–4236. 2016.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Smatlikova P, Askeland G, Vaskovicova M,
Klima J, Motlik J, Eide L and Ellederová Z: Age-related oxidative
changes in primary porcine fibroblasts expressing mutated
huntingtin. Neurodegener Dis. 19:22–34. 2019.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Zhou H, Xu M, Huang Q, Gates AT, Zhang XD,
Castle JC, Stec E, Ferrer M, Strulovici B, Hazuda DJ and Espeseth
AS: Genome-scale RNAi screen for host factors required for HIV
replication. Cell Host Microbe. 4:495–504. 2008.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Shinmura K, Kato H, Kawanishi Y, Igarashi
H, Goto M, Tao H, Inoue Y, Nakamura S, Misawa K, Mineta H and
Sugimura H: Abnormal expressions of DNA glycosylase genes NEIL1,
NEIL2, and NEIL3 are associated with somatic mutation loads in
human cancer. Oxid Med Cell Longev. 2016(1546392)2016.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Kim YS, Kim Y, Choi JW, Oh HE and Lee JH:
Genetic variants and risk of prostate cancer using pathway analysis
of a genome-wide association study. Neoplasma. 63:629–634.
2016.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Klattenhoff AW, Thakur M, Chu CS, Ray D,
Habib SL and Kidane D: Loss of NEIL3 DNA glycosylase markedly
increases replication associated double strand breaks and enhances
sensitivity to ATR inhibitor in glioblastoma cells. Oncotarget.
8:112942–112958. 2017.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Jiraskova K, Hughes DJ, Brezina S,
Gumpenberger T, Veskrnova V, Buchler T, Schneiderova M, Levy M,
Liska V, Vodenkova S, et al: Functional polymorphisms in DNA repair
genes are associated with sporadic colorectal cancer susceptibility
and clinical outcome. Int J Mol Sci. 20(97)2018.PubMed/NCBI View Article : Google Scholar
|
|
22
|
de Sousa JF, Torrieri R, Searfim RB, Di
Cristofaro LF, Escanfella DF, Ribeiro R, Zanette DL, Paçó-Larson
ML, da Silva WA Jr, Tirapelli DP, et al: Expression signatures of
DNA repair genes correlate with survival prognosis of astrocytoma
patients. Tumour Biol. 39(1010428317694552)2017.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Matta J, Morales L, Dutil J, Bayona M,
Alvarez C and Suarez E: Differential expression of DNA repair genes
in Hispanic women with breast cancer. Mol Cancer Biol.
1(54)2013.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Nwani NG, Condello S, Wang Y, Swetzig WM,
Barber E, Hurley T and Matei D: A novel ALDH1A1 inhibitor targets
cells with stem cell characteristics in ovarian cancer. Cancers
(Basel). 11(502)2019.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Barry KH, Koutros S, Berndt SI, Andreotti
G, Hoppin JA, Sandler DP, Burdette LA, Yeager M, Freeman LE, Lubin
JH, et al: Genetic variation in base excision repair pathway genes,
pesticide exposure, and prostate cancer risk. Environ Health
Perspect. 119:1726–1732. 2011.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Zhou J, Chan J, Lambele M, Yusufzai T,
Stumpff J, Opresko PL, Thali M and Wallace SS: NEIL3 repairs
telomere damage during S phase to secure chromosome segregation at
mitosis. Cell Rep. 20:2044–2056. 2017.PubMed/NCBI View Article : Google Scholar
|
|
27
|
McNally EJ, Luncsford PJ and Armanios M:
Long telomeres and cancer risk: The price of cellular immortality.
J Clin Invest. 130:3474–3481. 2019.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Chen X, Tang WJ, Shi JB, Liu MM and Liu
XH: Therapeutic strategies for targeting telomerase in cancer. Med
Res Rev. 40:532–585. 2020.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Zhang H, Ma H, Wang Q, Chen M, Weng D,
Wang H, Zhou J, Li Y, Sun J, Chen Y, et al: Analysis of loss of
heterozygosity on chromosome 4q in hepatocellular carcinoma using
high-throughput SNP array. Oncol Rep. 23:445–455. 2010.PubMed/NCBI
|
|
30
|
Masters JR, Thomson JA, Daly-Burns B, Reid
YA, Dirks WG, Packer P, Toji LH, Ohno T, Tanabe H, Arlett CF, et
al: Short tanderm repeat profiling provides an international
reference standard for human cell lines. Proc Natl Acad Sci USA.
98:8012–8017. 2001.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Bland JM and Altman DG: Survival
probabilities (the Kaplan-Meier method). BMJ.
317(1572)1998.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Tran OT, Tadesse S, Chu C and Kidane D:
Overexpression of NEIL3 associated with altered genome and poor
survival in selected types of human cancer. Tumour Biol.
42(1010428320918404)2020.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Fujimoto A, Furuta M, Totoki Y, Tsunoda T,
Kato M, Shiraishi Y, Tanaka H, Taniguchi H, Kawakami Y, Ueno M, et
al: Whole-genome mutational landscape and characterization of
noncoding and structural mutations in liver cancer. Nat Genet.
48:500–509. 2016.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Ma G, Yang X, Liang Y, Wang L, Li D, Chen
Y, Liang Z, Wang Y and Niu H: Precision medicine and bladder cancer
heterogeneity. Bull Cancer. 105:925–931. 2018.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Constantinidou A, Alifieris C and Trafalis
DT: Targeting programmed cell death-1 (PD-1) and ligand (PD-L1): A
new era in cancer active immunotherapy. Pharmacol Ther. 194:84–106.
2019.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Tella SH, Mahipal A, Kommalapati A and Jin
Z: Evaluating the safety and efficacy of Nivolumab in patients with
advanced hepatocellular carcinoma: Evidence to date. Onco Targets
Ther. 12:10335–10342. 2019.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Blum A, Wang P and Zenklusen JC: SnapShot:
TCGA-analyzed tumors. Cell. 173(530)2018.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Fouad YA and Aanei C: Revisiting the
hallmarks of cancer. Am J Cancer Res. 7:1016–1036. 2017.PubMed/NCBI
|
|
40
|
Ribatti D: A revisited concept: Contact
inhibition of growth. From cell biology to malignancy. Exp Cell
Res. 359:17–19. 2017.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Barnum KJ and Q'Connell MJ: Cell cycle
regulation by checkpoints. Methods Mol Biol. 1170:29–40.
2014.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Wenzel ES and Singh ATK: Cell-cycle
checkpoints and aneuploidy on the path to cancer. In Vivo. 32:1–5.
2018.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Tuzlak S, Kaufmann T and Villunger A:
Interrogating the relevance of mitochondrial apoptosis for
vertebrate development and postnatal tissue homeostasis. Genes Dev.
30:2133–2151. 2016.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Goldar S, Khaniani MS, Derakhshan SM and
Baradaran B: Molecular mechanisms of apoptosis and roles in cancer
development and treatment. Asian Pac J Cancer Prev. 16:2129–2144.
2015.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Engelman JA, Luo J and Cantley LC: The
evolution of phosphatidylinositol 3-kinases as regulators of growth
and metabolism. Nat Rev Genet. 7:606–619. 2006.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Czech MP: PIP2 and PIP3: Complex roles at
the cell surface. Cell. 100:603–606. 2000.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Dowling RJ, Topisirovic I, Fonseca DB and
Sonenberg N: Dissecting the role of mTOR: Lessons from mTOR
inhibitors. Biochim Biophys Acta. 1804:433–439. 2010.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Hay N and Sonenberg N: Upstream and
downstream of mTOR. Genes Dev. 18:1926–1945. 2014.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Chen QY and Costa M: PI3K/Akt/mTOR
signaling pathway and the biphasic effect of arsenic in
carcinogenesis. Mol Pharmacol. 94:784–792. 2018.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Li X, Wu C, Chen N, Gu H, Yen A, Cao L,
Wang E and Wang L: PI3K/Akt/mTOR signaling pathway and targeted
therapy for glioblastoma. Oncotarget. 7:33440–33450.
2016.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Kattan SW, Nafie MS, Elmgeed GA, Alelwani
W, Badar M and Tantawy MA: Molecular docking, anti-proliferative
activity and induction of apoptosis in human liver cancer cells
treated with androstane derivatives: Implication of PI3K/AKT/mTOR
pathway. J Steroid Biochem Mol Biol. 198(105604)2020.PubMed/NCBI View Article : Google Scholar
|
